Common medication for heart failure patients does not increase activity level

Heart failure patients with preserved ejection fraction -- where the heart becomes stiff and cannot relax or fill properly -- did not have increased exercise tolerance after taking isosorbide mononitrate, compared to a placebo.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Condition:   Heart Failure Interventions:   Other: Immediate ENABLE nurse coaching, on top of usual care;   Other: Usual Care Sponsors:   National Cancer Centre, Singapore;   Ministry of Health, Singapore;   National Medical Research Council (NMRC), Singapore Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Functional Tricuspid Regurgitation Intervention:   Diagnostic Test: Transthoracic Echocardiography Sponsors:   Foundation IRCCS San Matteo Hospital;   Cardarelli Hospital;   Fondazione C.N.R./Regione Toscana " G. Monasterio " , Pisa, Italy;   Monaldi Hospital;   Federico II University;   Cava de Tirreni Costiera Amalfitana Hospital Salerno;   Umberto I Hospital, Nocera Inferiore;   Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona;   Azienda Os...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study provides novel therapeutic strategies for CHF treatment.PMID:35083842 | DOI:10.1111/jcmm.17160
Source: Molecular Medicine - Category: Molecular Biology Authors: Source Type: research
CONCLUSION: Ghrelin inhibits the phosphorylation and nuclear entry of ERK by activating PTEN, thereby controlling the transcription of hypertrophic genes, improving myocardial hypertrophy, and enhancing cardiac function.PMID:35082908 | PMC:PMC8786517 | DOI:10.1155/2022/1045681
Source: Computational and Mathematical Methods in Medicine - Category: Statistics Authors: Source Type: research
Nat Rev Clin Oncol. 2022 Jan 26. doi: 10.1038/s41571-022-00600-w. Online ahead of print.ABSTRACTThe development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer treatment, enabling the possibility of long-term survival in patients with metastatic disease, and providing new therapeutic indications in earlier-stage settings. As such, characterizing the long-term implications of receiving ICIs has grown in importance. An abundance of evidence exists describing the acute clinical toxicities of these agents, although chronic effects have not been as well catalogued. Nonetheless, emerging evidence indicate...
Source: Atherosclerosis - Category: Cardiology Authors: Source Type: research
CONCLUSIONS: The increase of DAPK1 may be related to the pathogenesis of AMI. DAPK1 inhibitors protect cardiomyocytes from AMI-induced myocardial injury by reducing levels of inflammation and oxidative stress in myocardial tissue and cells.PMID:35082934 | PMC:PMC8786546 | DOI:10.1155/2022/9651092
Source: Disease Markers - Category: Laboratory Medicine Authors: Source Type: research
Circ J. 2022 Jan 27. doi: 10.1253/circj.CJ-21-0786. Online ahead of print.ABSTRACTBACKGROUND: Many patients with dilated cardiomyopathy (DCM) progress to heart failure (HF), although some demonstrate left ventricular (LV) reverse remodeling (LVRR), which is associated with better outcomes. The pulmonary artery diameter (PAD) to ascending aortic diameter (AoD) ratio has been used as a prognostic predictor in patients with HF, although this tool's usefulness in predicting LVRR remains unknown.Methods and Results:Data from a prospective observational study of 211 patients diagnosed in 2000-2020 with DCM were retrospectively a...
Source: Circulation Journal - Category: Cardiology Authors: Source Type: research
This study provides novel therapeutic strategies for CHF treatment.PMID:35083842 | DOI:10.1111/jcmm.17160
Source: J Cell Mol Med - Category: Molecular Biology Authors: Source Type: research
AbstractAimsRoutine, intermittent inotropic therapy (IIT) is still applied in advanced heart failure (HF) patients either as a bridge to definitive treatment or as a mean to improve quality of life (QOL), despite limited evidence to support its' use. Given recent reports of improved QOL and reduced HF hospitalization, with levosimendan compared with placebo in advanced HF patients, we aimed to assess the effects of switching a small group of milrinone-treated patients to levosimendan. This was performed as part of a protocol for changing our ambulatory HF clinic milrinone-based IIT to levosimendan.Methods and resultsSingle...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Short Communication Source Type: research
ConclusionWe present the ESC HFA QIs for HF, describe their development process and provide the scientific rationale for their selection. The indicators may be used to quantify and improve adherence to guideline-recommended clinical practice and thus improve patient outcomes.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: POSITION PAPERS Source Type: research
More News: Cardiology | Heart | Heart Failure | Isosorbide Mononitrate | Science | Sports Medicine